

Health Technology Clinical Committee

Date: May 16, 2014
Time: 8:00 am – 5:00 pm
Location: SeaTac Airport Conference Center
Adopted:

Meeting materials and transcript are available on the HTA website at:

<http://www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials.aspx>

HTCC DRAFT MINUTES

Members Present: C. Craig Blackmore, MD, MPH; Marie-Annette Brown, PhD, RN; Joann Elmore, MD MPH; Carson E. Odegard, DC, MPH; Richard C. Phillips, MD, MS, MPH; Seth Schwartz, MD, MPH; Michelle Simon, PhD, ND; Michael Souter, MB, Ch-B, DA, Christopher Standaert, MD; Kevin Walsh, MD

HTCC FORMAL ACTION

- 1. Call to Order:** Dr. Blackmore, Chair, called the meeting to order. Sufficient members were present to constitute a quorum.
- 2. March 21, 2014, Meeting Minutes:** Chair referred members to the draft minutes; motion to approve and second, and adopted by the committee.

Action: Ten committee members approved the March 21, 2014 meeting minutes. One member was absent.

- 3. Nonpharmacological Treatments for Treatment-resistant Depression Draft Findings & Decision:** Chair referred members to the draft findings and decision and called for further discussion. Two comments were received on the draft decision.

Action: Ten committee members approved the Nonpharmacological Treatments for Treatment-resistant Depression Findings & Decision document.

- 4. Facet Neurotomy Draft Findings & Decision:** Chair referred members to the draft findings and decision and called for further discussion. Nine comments were received on the draft decision. All comments are published with the [May 16, meeting materials](#).

Action: Ten committee members approved the Facet Neurotomy Findings & Decision document.

5. Proton Beam Therapy

Scheduled and Open Public Comments: The Chair called for public comments. Open public comments were presented by:

- Shannon MacDonald, MD
- Ralph Ermoian, MD
- George E. Laramore, MD, PhD

Draft

- Ramesh Rengan, MD, PhD
- Eugene B. Hug
- Robin Baird
- Norman E. Hubbard
- David Shepard
- Vivek Mehta

Presentation materials and conflict of interest forms are available with [May 16, meeting materials](#).

Agency Utilization and Outcomes:

Daniel Lessler, MD, MHA, Chief Medical Officer, WA Health Care Authority presented the state agency utilization rates for Proton Beam Therapy to the committee. The full presentation is published with [May 16, meeting materials](#).

Vendor Report and HTCC Q & A:

The Chair introduced the clinical expert for Proton Beam Therapy, Lia M Halasz, MD, University of Washington School of Medicine.

Daniel A. Ollendorf, MPH, of the Institute for Clinical and Economic Research (ICER), presented the evidence review addressing Proton Beam Therapy. The full presentation is published with [May 16, meeting materials](#).

Committee Discussion and Decision:

The HTCC reviewed and considered the Proton Beam Therapy technology assessment report and information provided by the state agencies. They also heard comments from the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. [See transcript for full committee deliberations.]

Proton Beam Therapy

| HTCC Committee Coverage Determination Vote | | | |
|---|-------------|-------------------------|----------------------------------|
| | Not Covered | Covered Unconditionally | Covered Under Certain Conditions |
| Ocular tumors | 0 | 0 | 10 |
| Pediatric cancers | 0 | 0 | 10 |
| Central nervous system tumors | 0 | 0 | 10 |
| Non-metastatic tumors with prior radiation in the treatment field | 0 | 0 | 10 |

Discussion

The committee determined a vote of coverage for Proton Beam Therapy with conditions.

Limitations of Coverage:

Proton Beam Therapy is a **covered benefit with conditions** for:

- Ocular tumors
- Pediatric cancers (e.g., medulloblastoma, retinoblastoma, Ewing's sarcoma)
- Central nervous system tumors (e.g., brain, spinal and paraspinal tumors)
- Other non-metastatic cancers with the following conditions:
 - Patient has had prior radiation in the expected treatment field with contraindication to all other forms of therapy, and
 - At agency discretion.

Non-Covered Indicators

Proton Beam Therapy is not covered for all other conditions.

Action

The committee checked for availability of a Medicare coverage decision. CMS does not have a national coverage determination (NCD) for Proton Beam Therapy, but does have a local coverage determination (LCD).

The committee reviewed selected clinical guidelines from the National Comprehensive Cancer Network, American Society for Radiation Oncology, American College of Radiology, American Cancer Society and Alberta Health Services. The committee also reviewed training standards published by the American College of Radiology and joint publications with the American Society for Radiation Oncology and the American Association of Physicists in Medicine.

The committee Chair directed HTA staff to prepare a Findings and Decision document on Proton Beam Therapy reflective of the majority vote for final approval at the next public meeting.

6. Draft Key Questions

The Chair directed members to review draft key questions proposed for technical assessment of Functional Neuroimaging for Primary Degenerative Dementia or Mild Cognitive Impairment and Screening & Monitoring Tests for Osteopenia/ Osteoporosis.

The Chair called for further comments. No further comment on the draft key questions.

7. Meeting adjourned.